[go: up one dir, main page]

MA29025B1 - Anticorps anti-glypicane 3 a chaine sucree modifiee - Google Patents

Anticorps anti-glypicane 3 a chaine sucree modifiee

Info

Publication number
MA29025B1
MA29025B1 MA29912A MA29912A MA29025B1 MA 29025 B1 MA29025 B1 MA 29025B1 MA 29912 A MA29912 A MA 29912A MA 29912 A MA29912 A MA 29912A MA 29025 B1 MA29025 B1 MA 29025B1
Authority
MA
Morocco
Prior art keywords
glypican
antibody
sugar chain
modified sugar
modified
Prior art date
Application number
MA29912A
Other languages
English (en)
Inventor
Kiyotaka Nakano
Izumi Sugo
Masamichi Sugimoto
Takahiro Ishiguro
Megumi Tanaka
Shigeyuki Iijima
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MA29025B1 publication Critical patent/MA29025B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MA29912A 2004-10-26 2007-05-17 Anticorps anti-glypicane 3 a chaine sucree modifiee MA29025B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004311356 2004-10-26

Publications (1)

Publication Number Publication Date
MA29025B1 true MA29025B1 (fr) 2007-11-01

Family

ID=36227980

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29912A MA29025B1 (fr) 2004-10-26 2007-05-17 Anticorps anti-glypicane 3 a chaine sucree modifiee

Country Status (19)

Country Link
US (2) US7867734B2 (fr)
EP (1) EP1816140A4 (fr)
JP (1) JP4794457B2 (fr)
KR (1) KR101296931B1 (fr)
CN (1) CN101068836B (fr)
AU (1) AU2005297772B2 (fr)
BR (1) BRPI0518279A2 (fr)
CA (1) CA2585196C (fr)
CR (1) CR9151A (fr)
IL (1) IL182662A (fr)
MA (1) MA29025B1 (fr)
MX (1) MX2007004593A (fr)
NO (1) NO20072366L (fr)
NZ (1) NZ554940A (fr)
RU (1) RU2451030C2 (fr)
TW (1) TWI468514B (fr)
UA (1) UA93488C2 (fr)
WO (1) WO2006046751A1 (fr)
ZA (1) ZA200703888B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
ATE474921T1 (de) * 2003-06-18 2010-08-15 Chugai Pharmaceutical Co Ltd Fucosetransporter
CA2544692C (fr) 2004-07-09 2014-04-01 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-glypican 3
EP1800693B1 (fr) 2004-08-24 2013-07-17 Chugai Seiyaku Kabushiki Kaisha Therapie adjuvante utilisant des anticorps anti-glypicane 3
WO2006046751A1 (fr) * 2004-10-26 2006-05-04 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-glypicane 3 à chaîne sucrée modifiée
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
MX2010000537A (es) * 2007-07-17 2010-03-25 Medarex Inc Anticuerpos monoclonales contra glipicano-3.
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
KR20100085067A (ko) * 2007-09-28 2010-07-28 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US8326958B1 (en) 2009-01-28 2012-12-04 Headwater Partners I, Llc Service activation tracking system
US8589541B2 (en) 2009-01-28 2013-11-19 Headwater Partners I Llc Device-assisted services for protecting network capacity
US11985155B2 (en) 2009-01-28 2024-05-14 Headwater Research Llc Communications device with secure data path processing agents
US12389218B2 (en) 2009-01-28 2025-08-12 Headwater Research Llc Service selection set publishing to device agent with on-device service selection
US12452377B2 (en) 2009-01-28 2025-10-21 Headwater Research Llc Service design center for device assisted services
US12166596B2 (en) 2009-01-28 2024-12-10 Disney Enterprises, Inc. Device-assisted services for protecting network capacity
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP3557260B1 (fr) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Médicament de ciblage gpc3 administré à un patient en réponse à une thérapie médicamenteuse de ciblage gpc3
EP3094718A4 (fr) * 2014-01-16 2017-06-07 Calysta, Inc. Micro-organismes pour la production améliorée d'amino-acides et procédés associés
US11760807B2 (en) 2014-05-08 2023-09-19 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7096667B2 (ja) 2015-07-01 2022-07-06 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
EP3889184A1 (fr) * 2015-08-03 2021-10-06 Cafa Therapeutics Limited Anticorps dirigé contre glypicane-3 et application associée
KR101796688B1 (ko) * 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
CA3011734A1 (fr) 2016-01-27 2017-08-03 Medimmune, Llc Procede de preparation d'anticorps ayant un profil de glycosylation defini
TWI759287B (zh) 2016-03-15 2022-04-01 日商中外製藥股份有限公司 使用ｐｄ－１軸結合拮抗劑和抗ｇｐｃ３抗體治療癌症的方法
CN110035768A (zh) 2016-07-26 2019-07-19 泰莎治疗私人有限公司 嵌合抗原受体
US11793180B2 (en) 2016-08-22 2023-10-24 Chugai Seiyaku Kabushiki Kaisha Gene-modified mouse expressing human GPC3 polypeptide
CN106591371A (zh) * 2016-11-25 2017-04-26 哈尔滨百伊生生物科技有限公司 Cd16a/gpc3双抗慢病毒表达载体及其构建方法和应用
WO2019059411A1 (fr) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha Posologie pour polythérapie utilisant des antagonistes de liaison d'axe pd-1 et un agent de ciblage gpc3
AU2019354395A1 (en) 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors
CN119896730A (zh) 2018-12-17 2025-04-29 雷维托普有限公司 双免疫细胞衔接物
WO2020242950A1 (fr) * 2019-05-24 2020-12-03 Elixiron Immunotherapeutics (hong Kong) Limited Anticorps anti-csf1r, protéines de fusion il10 et leurs utilisations
WO2020246563A1 (fr) 2019-06-05 2020-12-10 中外製薬株式会社 Molécule de liaison à un site de clivage d'anticorps
EP4121516A4 (fr) * 2020-03-18 2024-06-05 Eutilex Co., Ltd. Compositions de cellules car t gpc3 et leurs procédés de fabrication et d'utilisation
WO2022171100A1 (fr) * 2021-02-10 2022-08-18 江苏先声药业有限公司 Anticorps gpc3 humanisé et son utilisation

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0242355A (ja) 1988-08-02 1990-02-13 Hitachi Constr Mach Co Ltd 超音波検査装置
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04336051A (ja) 1991-05-10 1992-11-24 Toshiba Corp 超音波診断装置
WO1993022332A2 (fr) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
AU724133B2 (en) * 1997-02-12 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Remedies for lymphocytic tumors
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
IL135221A0 (en) * 1997-10-03 2001-05-20 Chugai Pharmaceutical Co Ltd Natural humanized antibody and methods for the preparation thereof
JPH11118775A (ja) 1997-10-09 1999-04-30 Canon Inc 超音波検査装置
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2270150B2 (fr) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
JP3606132B2 (ja) 1999-10-14 2005-01-05 Ｊｆｅエンジニアリング株式会社 超音波探傷方法およびその装置
JP2002048867A (ja) 2000-08-07 2002-02-15 Mitsubishi Heavy Ind Ltd 音響探査装置
CA2421942C (fr) 2000-09-12 2009-10-20 Union Carbide Chemicals & Plastics Technology Corporation Composites polymeriques contenant des copolymeres d'oxyde d'alkylene
EP3690043A1 (fr) * 2000-10-06 2020-08-05 Kyowa Kirin Co., Ltd. Cellule produisant une composition d'anticorps
JP4336051B2 (ja) 2001-01-31 2009-09-30 株式会社エヌ・ティ・ティ・ドコモ 無線通信端末、発呼制限方法及びプログラム
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
KR100953520B1 (ko) * 2001-06-22 2010-04-21 츄가이 세이야꾸 가부시키가이샤 항글리피칸 3항체를 포함하는 항암제
MXPA04001072A (es) * 2001-08-03 2005-02-17 Glycart Biotechnology Ag Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
JP4087098B2 (ja) 2001-11-14 2008-05-14 株式会社東芝 超音波検査装置
JP3961359B2 (ja) 2002-07-18 2007-08-22 株式会社東芝 超音波画像化装置
WO2003042686A1 (fr) 2001-11-14 2003-05-22 Kabushiki Kaisha Toshiba Echographe, transducteur ultrasons, instrument d'examen et dispositif d'ultrasonographie
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2003085119A1 (fr) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
BRPI0311233B8 (pt) 2002-05-23 2021-07-27 Sunnybrook And Womens College Health Sciences Centre métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra
WO2004018667A1 (fr) 2002-08-26 2004-03-04 Kirin Beer Kabushiki Kaisha Peptides et medicaments les contenant
AU2002328429A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
WO2004023145A1 (fr) 2002-09-04 2004-03-18 Perseus Proteomics Inc. Procede de detection du cancer par detection du gpc3
AU2002338020A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20080008710A1 (en) 2003-09-04 2008-01-10 Hiroyuki Aburatani Therapeutic Agent And Diagnostic Agent For Cholangiocarcinoma
ITBO20040008U1 (it) 2004-02-03 2004-05-03 Tonazzi S R L Macchina per il riempimento e la chiusura di tubetti
CA2544692C (fr) 2004-07-09 2014-04-01 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-glypican 3
DE602005024147D1 (de) * 2004-08-08 2010-11-25 Eli Khayat Pharmazeutische zusammensetzungen zur linderung von übermässig hohen zuckerspiegeln bei diabetikern
US20060040325A1 (en) 2004-08-16 2006-02-23 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity
EP1800693B1 (fr) 2004-08-24 2013-07-17 Chugai Seiyaku Kabushiki Kaisha Therapie adjuvante utilisant des anticorps anti-glypicane 3
WO2006046751A1 (fr) * 2004-10-26 2006-05-04 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-glypicane 3 à chaîne sucrée modifiée
US20090061485A1 (en) * 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
JP5334319B2 (ja) * 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
AU2009226423B2 (en) * 2008-03-17 2014-11-27 Chugai Seiyaku Kabushiki Kaisha Method for detection of liver cancer cell using anti-glypican-3 antibody
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.

Also Published As

Publication number Publication date
RU2451030C2 (ru) 2012-05-20
JPWO2006046751A1 (ja) 2008-05-22
TW200621980A (en) 2006-07-01
JP4794457B2 (ja) 2011-10-19
ZA200703888B (en) 2009-11-25
KR20070070222A (ko) 2007-07-03
IL182662A (en) 2014-09-30
US7867734B2 (en) 2011-01-11
US20110033452A1 (en) 2011-02-10
CA2585196C (fr) 2015-01-06
CN101068836A (zh) 2007-11-07
CR9151A (es) 2008-03-18
NO20072366L (no) 2007-06-21
EP1816140A1 (fr) 2007-08-08
HK1110335A1 (en) 2008-07-11
BRPI0518279A2 (pt) 2008-11-11
MX2007004593A (es) 2007-06-22
CN101068836B (zh) 2013-08-14
RU2007119579A (ru) 2008-12-10
CA2585196A1 (fr) 2006-05-04
TWI468514B (zh) 2015-01-11
KR101296931B1 (ko) 2013-08-14
UA93488C2 (uk) 2011-02-25
EP1816140A4 (fr) 2009-09-02
US20080124330A1 (en) 2008-05-29
NZ554940A (en) 2010-04-30
WO2006046751A1 (fr) 2006-05-04
IL182662A0 (en) 2007-09-20
AU2005297772A1 (en) 2006-05-04
AU2005297772B2 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
MA29025B1 (fr) Anticorps anti-glypicane 3 a chaine sucree modifiee
EP1616881A4 (fr) Anticorps anti-mpl
EP1709080A4 (fr) Anticorps a madcam
EP1648341A4 (fr) Chaine d'annuloplastie
DE602005001159D1 (de) Verpackung mit Originalitätssicherung
NL1029105A1 (nl) Tetraazabenz[e]azuleenderivaten en analogen daarvan.
NO20044347L (no) Anti-alfavbeta6-antistoff
LT1824988T (lt) Nukreipta į užduotą saitą fviii modifikacija
EP1964852A4 (fr) Anticorps anti-ilt7
EP1850873A4 (fr) Anticorps anti-tgf-beta
DK1599504T3 (da) Modificeret antistof
NO20040789L (no) Forbedret pakning med integrerte sensorer.
FR2855020B3 (fr) Chaine de charme
DK1757820T3 (da) Fastgørelsesindretning for strukturelement
EP1848273A4 (fr) Macrocycles a 18 chainons et leurs analogues
DE502005007018D1 (de) Sensorleuchte
DE50309063D1 (de) Kraftsensor
DE502005004791D1 (de) Messfühler mit Selbsttest
DE60332801D1 (de) Kettenspanner
EP1555976A4 (fr) Propofol associe a la cysteine
NO20045464L (no) Palleteringssystem
EP1666501A4 (fr) Anticorps anti-hm1.24 a chaine de sucre modifiee
FR2870039B1 (fr) Autotransformateur a dephasage de 40 degres
EP1956035A4 (fr) Derive de polyisocyanure dont la chaine principale presente une structure helicoidale modulee
DE602004015579D1 (de) Orientierungssensor